RetaCalc
Protocol library
SingleApproved OtherMixedLow confidenceSourced

Sermorelin

A short growth-hormone-releasing hormone analogue with historical diagnostic and paediatric clinical use. Current research products may not match former medicines.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideNightly
Third-party educational schedule for a 5 mg research vial

200 mcg nightly in weeks 1-2, 300 mcg in weeks 3-4, 400 mcg in weeks 5-6 and 500 mcg in weeks 7-8

The schedule reflects community and historical practice, not a current matched product label. Former paediatric medicines do not establish equivalence for research vials.

View source

Evidence summary

A short growth-hormone-releasing hormone analogue with historical diagnostic and paediatric clinical use. Current research products may not match former medicines.

Protocol basis

The evidence base contains historical diagnostic and therapeutic protocols, but product availability and formulation identity have changed. A current universal schedule is not supportable.

What remains uncertain

Equivalence to former labelled products, adult wellness benefit, optimal monitoring and long-term safety remain uncertain.

Warnings and contraindications

Historical authorised formulations do not automatically validate current research vials.
Use in growth disorders relied on diagnosis, growth monitoring and endocrine laboratory testing.
Growth hormone and IGF-1 effects carry systemic metabolic risks.